March 20, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that alleged the growth of male breast tissue (Risperdal gynecomastia) suffered by the plaintiff was stopped dead in its tracks before a trial reached the verdict stage after a Pennsylvania judge determined that Johnson & Johnson (J&J) and its Risperdal unit, Janssen Pharmaceuticals Inc. (Janssen) had not failed to adequately warn about gynecomastia risk as the plaintiff had asserted, thus pulling the rug out from under the lawsuit.Read [ Recent Risperdal Lawsuit Tossed, Plaintiffs Plan to Appeal ]
March 7, 2017. By Deb Hipp.
New Brunswick, NJ:There are now 18,500 Risperdal lawsuits pending against Johnson & Johnson (J & J) and its subsidiary Janssen Pharmaceuticals in the US and Canada, according to Johnson & Johnson's most recent annual report.Read [ Number of Pending Risperdal Lawsuits Grows to 18,500 Cases ]
February 21, 2017. By Gordon Gibb.
Philadelphia, PA: With Risperdal side effects lawsuits continuing to grow at a compelling rate within a mass tort in the Philadelphia Court of Common Pleas, the file is poised to move forward with a meeting planned for March 9 with regard to the centralized litigation (In Re: Risperdal Litigation, Case No. 100300296).Read [ Risperdal Case Load Shows No Sign of Slowing Down ]
February 10, 2017. By Deb Hipp.
Toronto, ON: A recent Canadian study found that nearly 12 percent of Ontario youth diagnosed with attention deficit hyperactivity disorder (ADHD) are prescribed antipsychotic drugs such as Risperdal (Risperidone), Zyprexa and Seroquel despite having no other mental health diagnoses.Read [ Canadian Study Finds 12 Percent of ADHD Youth Prescribed Antipsychotic Drugs Such as Risperdal ]
January 29, 2017. By Jane Mundy.
Philadelphia, PA: Litigation over the antipsychotic drug Risperdal was the second largest mass tort (just behind Reglan) in 2016 and believed to be mainly responsible for the pharmaceutical inventory in Philadelphia’s Complex Litigation Center to be “at its highest level in recent years.”Read [ Risperdal Litigation Second Largest ]
January 10, 2017. By Gordon Gibb.
Philadelphia, PA: As principles with Janssen Pharmaceuticals continued to maintain that pre-trial Risperdal settlements are one-offs and not an indication of any emerging strategy, Janssen nonetheless settled a Risperdal lawsuit Friday before what would have been the seventh Risperdal gynecomastia trial had a chance to start.Read [ Seventh Risperdal Gynecomastia Case Settled Prior to Trial ]
December 29, 2016. By Jane Mundy.
Baltimore, MD: Johnson & Johnson is accused of targeting Risperdal marketing towards children and teenagers, to the extent that the antipsychotic drug has been prescribed to treat anxiety in children. But some of those boys who developed gynecomastia, a non-cancerous increase in the size of male breast tissue, now suffer from depression and chances are, J&J has a drug for that too.Read [ Risperdal for Kids Reaps Big Bucks—but for how long? ]
December 10, 2016. By Gordon Gibb.
Philadelphia, PA: With the $70 million Risperdal settlement from back in the summer continuing to reverberate, the sixth bellwether Risperdal lawsuit as part of the Pennsylvania Mass Tort is underway. The plaintiff, a Nebraska man, is claiming in his Risperdal gynecomastia lawsuit that Risperdal is responsible for the growth of male breast tissue.Read [ Latest Bellwether Risperdal Lawsuit Underway in Philadelphia ]
November 29, 2016. By Heidi Turner.
Philadelphia, PA: Plaintiffs following recent Risperdal litigation news might be forgiven for thinking the latest awards and settlements are good news. After all, a Risperdal lawsuit that went to trial in the summer resulted in a $70 million jury award. Other awards to plaintiffs alleging they suffered Risperdal side effects also hit the million-dollar mark. And Janssen Pharmaceuticals reportedly settled a lawsuit for a confidential amount in recent months.Read [ Risperdal Awards Add Up For Plaintiffs ]
November 22, 2016. By Gordon Gibb.
Philadelphia, PA: Any assumption that Johnson & Johnson (J&J) settled a recent Risperdal lawsuit just prior to trial while peering through the rear-view mirror at a large plaintiff verdict from July is pure speculation, according to the attorney representing the plaintiffs. Still, with a $70 million judgement awarded to a Risperdal gynecomastia plaintiff just four months ago, such an assumption is understandable.Read [ Don’t Read Anything into $70 Million Risperdal Settlement: Attorney ]